MLN9708
MLN9708
CAS: 1239908-20-3
Molecular Formula: C20H23BCl2N2O9
MLN9708 - Names and Identifiers
| Name | MLN9708 |
| Synonyms | MLN9708 MLN 9708 IXAZOMIB MLN-9708 MLN-9708 IXAZOMIB CITRATE Ixazomib citrate (USAN) Ixazomib citrate(MLN9708) 2,2'-(2-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-5-oxo-1,3,2-dioxaborolane-4,4-diyl)diacetic acid 2-[(1R)-1-[[2-[(2,5-Dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diacetic acid (R)-2,2'-(2-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-5-oxo-1,3,2-dioxaborolane-4,4-diyl)diacetic acid 2-[4-(carboxymethyl)-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolan-4-yl]acetic acid |
| CAS | 1239908-20-3 |
MLN9708 - Physico-chemical Properties
| Molecular Formula | C20H23BCl2N2O9 |
| Molar Mass | 517.12 |
| Density | 1.47±0.1 g/cm3(Predicted) |
| Solubility | 10 mM in DMSO |
| pKa | 3.59±0.10(Predicted) |
| Storage Condition | -20℃ |
MLN9708 - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.934 ml | 9.669 ml | 19.338 ml |
| 5 mM | 0.387 ml | 1.934 ml | 3.868 ml |
| 10 mM | 0.193 ml | 0.967 ml | 1.934 ml |
| 5 mM | 0.039 ml | 0.193 ml | 0.387 ml |
Last Update：2024-01-02 23:10:35
MLN9708 - Reference Information
| indication | isazomib is a proteasome inhibitor suitable for use in combination with lenalidomide and dexamethasone for patients with multiple myeloma to receive at least one prior treatment. |
| recommended dose | recommended starting dose of 4 mg orally on days 1,8, and 15 of the 28-day course; the dose should be at least one hour before or at least 2 hours after the food is taken. |
| pharmacological action | isazomib induces apoptosis of multiple myeloma cell lines in vitro. Isazomib showed in vitro cytotoxicity to myeloma cells from patients who had relapsed after a variety of previous treatments, including bortezomib, lenalidomide, and dexamethasone. The combination of isazomib and lenalidomide showed a synergistic cytotoxic effect in multiple myeloma cell lines. In vivo, isazomib showed anti-tumor activity in a mouse multiple myeloma tumor xenograft model. |
| adverse reactions | The most common adverse reactions (≥ 20%) were Diarrhea, constipation, thrombocytopenia, peripheral neuropathy, nausea, peripheral edema, Vomit, and back pain. |
Last Update：2024-04-09 20:45:29
Supplier List
Spot supply
Product Name: Ixazomib Impurity 4 Visit Supplier Webpage Request for quotationCAS: 1239908-20-3
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Spot supply
Product Name: MLN9708 Request for quotationCAS: 1239908-20-3
Tel: +86-17551318830
Email: r@reformchem.com
Mobile: +86-17551318830
QQ: 3785839865
Product Name: MLN9708 Request for quotation
CAS: 1239908-20-3
Tel: 17505222756
Email: pules.cn@gmail.com
Mobile: +86-17551318830
Wechat: 17505222756
CAS: 1239908-20-3
Tel: 17505222756
Email: pules.cn@gmail.com
Mobile: +86-17551318830
Wechat: 17505222756
Spot supply
Product Name: MLN9708 Visit Supplier Webpage Request for quotationCAS: 1239908-20-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Ixazomib Impurity 4 Visit Supplier Webpage Request for quotationCAS: 1239908-20-3
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Spot supply
Product Name: MLN9708 Request for quotationCAS: 1239908-20-3
Tel: +86-17551318830
Email: r@reformchem.com
Mobile: +86-17551318830
QQ: 3785839865
Product Name: MLN9708 Request for quotation
CAS: 1239908-20-3
Tel: 17505222756
Email: pules.cn@gmail.com
Mobile: +86-17551318830
Wechat: 17505222756
CAS: 1239908-20-3
Tel: 17505222756
Email: pules.cn@gmail.com
Mobile: +86-17551318830
Wechat: 17505222756
Spot supply
Product Name: MLN9708 Visit Supplier Webpage Request for quotationCAS: 1239908-20-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History